Sumary of CAR-T extends EFS as second-line therapy for advanced B-cell lymphoma, topline data show:
- Lisocabtagene maraleucel extended EFS and PFS compared with high-dose chemotherapy and hematopoietic stem cell transplant for relapsed or refractory large B-cell lymphoma, according to topline data released by the agent manufacturer..
- Lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb) — also known as liso-cel — is a gene edited, autologous CAR T-cell therapy that targets the CD19 antigen expressed on the surface of cancer cells..
- The FDA approved the treatment earlier this year for adults with relapsed or refractory large B-cell lymphoma who received at least two prior therapies and did not have central nervous system disease..
- Safety results appeared consistent with previous studies of liso-cel as third-line therapy and no new safety issues have emerged during the TRANSFORM study, according to the press release..
- “We ambitiously designed the TRANSFORM trial to evaluate Breyanzi potential in the second-line setting for patients with relapsed or refractory large B-cell lymphoma against the standard-of-care regimen of high-dose chemotherapy and autologous stem cell transplant,”.
- Bristol Myers Squibb plans to conduct a complete analysis of the TRANSFORM trial data and present the results at an upcoming medical conference, according to the press release…